These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27322484)

  • 21. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Emens LA; Davidson NE
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Premature ovarian failure after chemotherapy for breast cancer].
    Mathelin C; Brettes JP; Diemunsch P
    Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology.
    Lambertini M; Cinquini M; Moschetti I; Peccatori FA; Anserini P; Valenzano Menada M; Tomirotti M; Del Mastro L
    Eur J Cancer; 2017 Jan; 71():25-33. PubMed ID: 27940355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
    Pan K; Chlebowski RT
    Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
    Burstein HJ; Lacchetti C; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Solky AJ; Stearns V; Winer EP; Griggs JJ
    J Clin Oncol; 2016 May; 34(14):1689-701. PubMed ID: 26884586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy regimens in early breast cancer: major controversies and future outlook.
    Joerger M; Thürlimann B
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):165-78. PubMed ID: 23406558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
    Del Mastro L; Levaggi A; Giraudi S; Pronzato P
    Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New options in adjuvant endocrine therapy in breast cancer].
    Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
    Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies in breast cancer: adjuvant and neoadjuvant therapy.
    Montemurro F; Redana S; Valabrega G; Aglietta M
    Expert Opin Pharmacother; 2005 Jun; 6(7):1055-72. PubMed ID: 15957962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
    Lu YS; Wong A; Kim HJ
    Front Oncol; 2021; 11():700722. PubMed ID: 34595110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.